Advancing a scalable and multifactorial exosome therapy to address the unmet needs of drug‑induced hearing loss

Cisplatin: lifesaving treatment, lasting hearing risk

The urgent need to prevent treatment-related hearing loss without compromising cancer care

How it works

Cisplatin kills tumour cells by damaging their DNA. It treats testicular, ovarian, cervical, breast, bladder, head & neck and lung cancers in adults and children.

Clinical benefit

2/3

of treated patients survive and remain cancer free

The hidden cost

Cisplatin also damages the inner ear, causing permanent, irreversible hearing loss.

Who is affected

40 - 60 %

of treated adults develop hearing loss.

60 %

of children affected.

Prevention today

Sodium thiosulfate (Pedmark)® - the only approved preventive treatment.

Paediatric
patients only

The research Gap

There is an urgent need for novel strategies that prevent or mitigate hearing loss without compromising treatment outcomes.

Life-long impact

Communication

Difficulty understanding speech and engaging in conversation

Education

Challenges in learning and academic achievement

Social interaction

Reduced participation and risk of isolation

Quality of life

Emotional, mental and daily life impacts

Understanding the challenge

Clinical success should not come at the cost of hearing

Platinum-based chemotherapy drugs, such as cisplatin, are widely used to treat a range of solid tumours in both adults and children, including testicular, ovarian, cervical, breast, bladder, head and neck, and lung cancers. Cisplatin exerts its anticancer effect by damaging the DNA of cancer cells, leading to their death and significantly improving patient survival outcomes. Today, more than two-thirds of patients treated with cisplatin survive and remain cancer-free.

Despite its clinical effectiveness, cisplatin is associated with serious side effects, including ototoxicity, a form of inner ear damage that can result in permanent hearing loss. Cisplatin-induced hearing loss affects approximately 40-60% of adult patients, with around 18% experiencing severe to profound hearing impairment. Children are particularly vulnerable, with up to 60% of paediatric patients receiving cisplatin developing hearing loss.

Hearing loss can have a profound impact on communication, education, social interactions, and overall quality of life. Currently, only one preventive treatment is available, and it is approved exclusively for paediatric patients, leaving adults with no options. Importantly, the use of systemic sodium thiosulfate in adult populations raises concerns regarding a potential reduction in the anticancer efficacy of cisplatin.

Therefore, there is an urgent need for novel strategies that can prevent or mitigate cisplatin-induced hearing loss without compromising treatment outcomes.

Our solution

Harnessing natural biological messages to protect the inner ear

EXO-OTO-01 is an experimental treatment being developed to protect hearing from damage caused by certain chemotherapy drugs. It harnesses the unique properties of umbilical cord blood through exosomes — tiny packages that carry natural biological messages between cells. These messages may help protect the delicate cells of the inner ear by reducing harmful stress and inflammation and supporting repair, therefore improving the quality of life of cancer patients treated with platinum compounds. Early studies in preclinical models have shown promising hearing protection, paving the way for further development towards human trials.

EVs

Complex molecular messages (e.g., microRNAs, proteins, and lipids)

Naturally secreted by cells; excellent safety profile

Advantages over cell-based approaches (i.e., easier manipulation, acellular, non-replicative, low immunogenicity)

Off-the-shelf product (ready-to-use and not patient-specific)

Umbilical Cord Blood

Non-invasive, ethically collected and processed

Abundant medical waste (circularity)

Strong immunomodulatory and regenerative potential of neonatal progenitor cells

Patient- and Stage-Agnostic Multifactorial Mode of Action with Durable Effects

Superior Source Material

Breakthrough Manufacturing Process Enabling GMP Scalability

Demonstrated Preclinical Performance

The project

From promising science towards future clinical trials

EXO-OTOProtect aims to bring a new approach to hearing protection closer to the people who need it. Supported by the European Union through the Horizon Europe EIC Pre-Accelerator programme, the project will advance EXO-OTO-01, an experimental treatment designed to help prevent hearing loss caused by platinum-based drugs, often used in chemotherapy.

We will refine how the treatment is formulated, identify the most suitable way to deliver it to the inner ear, and study its ability to protect hearing and its safety in preclinical models. Alongside this research, we will prepare for the regulatory and business steps needed to support future development.

These activities will lay the groundwork for future clinical trials, with the long-term goal of helping people preserve their hearing and quality of life during and after cancer treatment.

Updates

News & Events

Project news and event updates will be published here as EXO-OTOProtect progresses.

Updates coming soon

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Resources

Knowledge

European Commission

EXO-OTOProtect on CORDIS

Project ID: 101309861

Deliverables

Public deliverables will be available to download here.

Protecting hearing. Enabling treatment. Improving lives.

Coordinator

Exogenus Therapeutics SA

www.exogenus-t.com

Funded by the European Union under Grant Agreement Nr.101309861
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.